- Home
- ACHV vs IMRX Comparison
ACHV vs IMRX Comparison
Compare ACHV & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- IMRX
- Stock Information
- Founded
- ACHV N/A
- IMRX 2008
- Country
- ACHV Canada
- IMRX United States
- Employees
- ACHV N/A
- IMRX N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- IMRX Health Care
- Exchange
- ACHV Nasdaq
- IMRX Nasdaq
- Market Cap
- ACHV 72.5M
- IMRX 68.4M
- IPO Year
- ACHV N/A
- IMRX 2021
- Fundamental
- Price
- ACHV $3.35
- IMRX $2.60
- Analyst Decision
- ACHV Strong Buy
- IMRX Strong Buy
- Analyst Count
- ACHV 3
- IMRX 4
- Target Price
- ACHV $14.33
- IMRX $13.25
- AVG Volume (30 Days)
- ACHV 325.9K
- IMRX 2.4M
- Earning Date
- ACHV 08-12-2025
- IMRX 08-05-2025
- Dividend Yield
- ACHV N/A
- IMRX N/A
- EPS Growth
- ACHV N/A
- IMRX N/A
- EPS
- ACHV N/A
- IMRX N/A
- Revenue
- ACHV N/A
- IMRX N/A
- Revenue This Year
- ACHV N/A
- IMRX N/A
- Revenue Next Year
- ACHV N/A
- IMRX N/A
- P/E Ratio
- ACHV N/A
- IMRX N/A
- Revenue Growth
- ACHV N/A
- IMRX N/A
- 52 Week Low
- ACHV $1.84
- IMRX $1.00
- 52 Week High
- ACHV $5.31
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- ACHV 52.46
- IMRX 70.10
- Support Level
- ACHV $3.44
- IMRX $1.66
- Resistance Level
- ACHV $3.91
- IMRX $2.24
- Average True Range (ATR)
- ACHV 0.30
- IMRX 0.32
- MACD
- ACHV -0.09
- IMRX 0.07
- Stochastic Oscillator
- ACHV 28.03
- IMRX 89.51
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.